Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2013:7:2143-6.
doi: 10.2147/OPTH.S53243. Epub 2013 Oct 31.

Intravitreal anti-VEGF injection for the treatment of progressive juxtapapillary retinal capillary hemangioma: a case report and mini review of the literature

Elias Chelala  1 , Ali Dirani, Ali Fadlallah
Affiliations
Case Reports

Intravitreal anti-VEGF injection for the treatment of progressive juxtapapillary retinal capillary hemangioma: a case report and mini review of the literature

Elias Chelala et al. Clin Ophthalmol. 2013.

Abstract

We report a case of a patient known to have a von Hippel-Lindau disease with documented progressive juxtapapillary retinal capillary hemangioma (JRCH) with well-preserved visual acuity (VA) and visual field (VF). The patient received a single injection of intravitreal ranibizumab (IVR). Six months after IVR injection, the JRCH showed reduced vascularization, fibrosis, and mild shrinkage, and VA and VF remained unchanged. IVR therapy might therefore be considered as an alternative treatment for progressive JRCH, especially in patients with well-preserved VA and VF.

Keywords: intravitreal anti-VEGF injection; juxtapapillary retinal capillary hemangioma; von Hippel-Lindau disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Fundus photos of the left eye show the progression of the juxtapapillary retinal capillary hemangioma in 2008 (A), 2010 (B), 2011 (C), and 2012 (D).
Figure 2
Figure 2
Fluorescein angiography of the left eye in 2008 (A), 2010 (B), 2012 (C and 2013, 6 months after the single intravirtreal injection of ranibizumab (D).
Figure 3
Figure 3
The fundus photo of the left eye in 2013, 6 months after the single intravitreal injection of ranibizumab, shows decreased vascularization of the hemangioma and mild fibrosis.
See this image and copyright information in PMC

References

    1. Singh AD, Shields CL, Shields JA. von Hippel–Lindau disease. Surv Ophthalmol. 2001;46(2):117–142. - PubMed
    1. Singh AD, Nouri M, Shields CL, Shields JA, Perez N. Treatment of retinal capillary hemangioma. Ophthalmology. 2002;109(10):1799–1806. - PubMed
    1. Magee MA, Kroll AJ, Lou PL, Ryan EA. Retinal capillary hemangiomas and von Hippel–Lindau disease. Semin Ophthalmol. 2006;21(3):143–150. - PubMed
    1. Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, Laqua H. Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology. 2002;109(7):1256–1266. - PubMed
    1. Los M, Aarsman CJ, Terpstra L, et al. Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel–Lindau disease. Ann Oncol. 1997;8(10):1015–1022. - PubMed

Publication types

LinkOut - more resources